Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840116 | 0.90 | MAPK14 (0.44) | MAPK14OPRM1OPRD1CYP2D6CYP2C9 | |
| SCHEMBL4881027 | 0.88 | MAPK14 (0.42) | MAPK14OPRM1OPRD1CYP2D6CYP2C9 | |
| SCHEMBL4830537 | 0.86 | MAPK14 (0.42) | MAPK14OPRD1CYP2D6 | |
| SCHEMBL14109846 | 0.81 | MAPK14 (0.47) | MAPK14OPRM1OPRD1 | |
| SCHEMBL4509676 | 0.80 | MAPK14 (0.71) | MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4877440 | 0.79 | MAPK14 (0.66) | MAPK14 | |
| SCHEMBL14337927 | 0.77 | MAPK14 (0.49) | MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL14185143 | 0.77 | MAPK14 (0.49) | MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4830562 | 0.72 | MAPK14 (0.57) | MAPK14 | |
| SCHEMBL16573733 | 0.72 | MAPK14 (1.00) | MAPK14OPRM1OPRD1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393851-B2 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS INC. | 2005-12-29 | — | — | US | disclosed |
| US-20040176598-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK3 | MAPK14 21/4885OPRM1 2534/4885OPRD1 1644/4885 |
| US-20040176598-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK4 | MAPK14 11/4885OPRM1 2773/4885OPRD1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.